Category Archives: Biotech & Pharma

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) has been one of our biggest winners to date. When we first highlighted the company as being one to watch, back in October 2016, OWC was trading for $0.03 a share. By February 27, 2017, this had...

Like the Motley Fool website did, we also took a look at the recent spikes of the common stock price of Akari Therapeutics PLC (ADR) (NASDAQ: AKTX), which has returned more than 150% since the beginning of April, 2017. The clinical-stage biopharmaceutical...

It’s been a while since we last covered Kraig Biocraft Laboratories Inc (OTCMKTS:KBLB). The company is a very early stage biotech (although not a healthcare stock, we’ll get to this shortly) and in theory, its lead technology and...

Provectus Biopharmaceuticals Inc (OTCMKTS:PVCT) ran up to the tune of 22% on Friday, as the company announced the reestablishing of a Strategic Advisory Board (SAB). The news marks what many will see as a key step in the transitioning of Provectus...

We’ve been highlighting Pernix Therapeutics Holdings Inc (NASDAQ:PTX) as a potential buyout candidate for some time now. Since Sedor took over as interim Chief in May last year, and was subsequently appointed as permanent to the role a few...

Zoned Properties Inc (OTCMKTS:ZDPY) has had a pretty rough year so far. The company hit highs of $2.5 a share back in January, having opened 2017 in and around the $2.10 region. At the most recent close, however, Zoned was changing hands for...

Last week, we tried to figure out what might be next for New York based biotech company Immune Pharmaceuticals Inc (NASDAQ:IMNP), with the reverse split in the rear view mirror. Our conclusion was that the company has plenty of potential for...

Lexaria Bioscience Corp (OTCMKTS:LXRP) was analyzed by my colleague ‘Alex Carlson’ in this piece a few months ago. We recently received several mails from regular readers asking for an update. The stock has been quite bullish lately, so...

Interpace Diagnostics Group Inc (NASDAQ:IDXG) is all over the place right now. The company announced at the start of the week that it as picked up some coverage on its lead asset (well, one of then), and started to run on the back of the news....

GREAT BASIN SCIENT COM USD0.0001(POST REV SPLT (OTCMKTS:GBSND) is a tough one. It’s one we’ve looked at on a number of occasions in the past, and on each of these occasions, we’ve said pretty much the same thing – that its...

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter